{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:43:40Z","timestamp":1793720620847,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japan Society for the Promotion of Science (JAPS) KAKENHI","award":["21K08478"],"award-info":[{"award-number":["21K08478"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03558-z","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:22:14Z","timestamp":1744802534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Aya","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reika","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"3558_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","volume":"20","author":"X Lu","year":"2024","unstructured":"Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024;20:48\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"3558_CR2","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.","journal-title":"Front Immunol"},{"key":"3558_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","volume":"60","author":"W Wu","year":"2021","unstructured":"Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial lung disease in Anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021;60:293\u2013304.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3558_CR4","doi-asserted-by":"publisher","first-page":"1009546","DOI":"10.3389\/fimmu.2022.1009546","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang J, Yan B. Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: time to nip them in the bud. Front Immunol. 2022;13:1009546.","journal-title":"Front Immunol"},{"key":"3558_CR5","doi-asserted-by":"publisher","first-page":"833114","DOI":"10.3389\/fmed.2021.833114","volume":"8","author":"H Hu","year":"2022","unstructured":"Hu H, Yang H, Liu Y, Yan B. Pathogenesis of Anti-melanoma Differentiation-Associated gene 5 Antibody-Positive dermatomyositis: A concise review with an emphasis on type I interferon system. Front Med (Lausanne). 2022;8:833114.","journal-title":"Front Med (Lausanne)"},{"key":"3558_CR6","doi-asserted-by":"publisher","first-page":"103114","DOI":"10.1016\/j.autrev.2022.103114","volume":"21","author":"P Ruscitti","year":"2022","unstructured":"Ruscitti P, Di Cola I, Di Muzio C, Italiano N, Ursini F, Giacomelli R, et al. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Autoimmun Rev. 2022;21:103114.","journal-title":"Autoimmun Rev"},{"key":"3558_CR7","doi-asserted-by":"publisher","first-page":"152231","DOI":"10.1016\/j.semarthrit.2023.152231","volume":"62","author":"H Xie","year":"2023","unstructured":"Xie H, Zhang D, Wang Y, Shi Y, Yuan Y, Wang L, et al. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review. Semin Arthritis Rheum. 2023;62:152231.","journal-title":"Semin Arthritis Rheum"},{"key":"3558_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/mr\/road042","volume":"34","author":"B Yang","year":"2024","unstructured":"Yang B, Liu S, Qian Z, Tong Z. Predicting the death of patients with anti-melanoma differentiation-associated protein-5-positive dermatomyositis-associated interstitial lung disease: A systematic review and meta-analysis. Mod Rheumatol. 2024;34:541\u201350.","journal-title":"Mod Rheumatol"},{"key":"3558_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","volume":"158","author":"X Lian","year":"2020","unstructured":"Lian X, Zou J, Guo Q, Chen S, Lu L, Wang R, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest. 2020;158:1535\u201345.","journal-title":"Chest"},{"key":"3558_CR10","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","volume":"61","author":"J So","year":"2022","unstructured":"So J, So H, Wong VT, Ho R, Wu TY, Wong PC, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology (Oxford). 2022;61:4437\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR11","doi-asserted-by":"publisher","first-page":"1286973","DOI":"10.3389\/fimmu.2024.1286973","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Lv C, You H, Xu L, Yuan F, Li J, et al. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model. Front Immunol. 2024;15:1286973.","journal-title":"Front Immunol"},{"key":"3558_CR12","doi-asserted-by":"publisher","first-page":"1209282","DOI":"10.3389\/fimmu.2023.1209282","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Zhao X, Liu B, Zhao Y, Li X, Ma Z, et al. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Front Immunol. 2023;14:1209282.","journal-title":"Front Immunol"},{"key":"3558_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","volume":"293","author":"Q Jin","year":"2023","unstructured":"Jin Q, Fu L, Yang H, Chen X, Lin S, Huang Z, et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Intern Med. 2023;293:494\u2013507.","journal-title":"J Intern Med"},{"key":"3558_CR14","doi-asserted-by":"publisher","first-page":"908365","DOI":"10.3389\/fmed.2022.908365","volume":"9","author":"Q Niu","year":"2022","unstructured":"Niu Q, Zhao LQ, Ma WL, Xiong L, Wang XR, He XL, et al. A new predictive model for the prognosis of MDA5+ DM-ILD. Front Med (Lausanne). 2022;9:908365.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"3558_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41566","volume":"73","author":"T Gono","year":"2021","unstructured":"Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in Polymyositis\/Dermatomyositis-Associated interstitial lung disease. Arthritis Rheumatol. 2021;73:677\u201386.","journal-title":"Arthritis Rheumatol"},{"key":"3558_CR17","doi-asserted-by":"publisher","first-page":"860798","DOI":"10.3389\/fmed.2022.860798","volume":"9","author":"ZM Ouyang","year":"2022","unstructured":"Ouyang ZM, Lin JZ, Tang AJ, Yang ZH, Yang LJ, Wei XN, et al. A matrix prediction model for the 6-Month mortality risk in patients with Anti-Melanoma Differentiation-Associated Protein-5-Positive dermatomyositis. Front Med (Lausanne). 2022;9:860798.","journal-title":"Front Med (Lausanne)"},{"key":"3558_CR18","doi-asserted-by":"publisher","first-page":"768052","DOI":"10.3389\/fmed.2021.768052","volume":"8","author":"W Xu","year":"2021","unstructured":"Xu W, Wu W, Zheng Y, Chen Z, Tao X, Zhang D, et al. A computed tomography Radiomics-Based prediction model on interstitial lung disease in Anti-MDA5-Positive dermatomyositis. Front Med (Lausanne). 2021;8:768052.","journal-title":"Front Med (Lausanne)"},{"key":"3558_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/rheumatology\/keab305","volume":"61","author":"W Wu","year":"2021","unstructured":"Wu W, Xu W, Sun W, Zhang D, Zhao J, Luo Q, et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Rheumatology (Oxford). 2021;61:230\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/joim.13154","volume":"289","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Koga T, Furukawa K, Horai Y, Fujikawa K, Okada A, et al. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis. J Intern Med. 2021;289:206\u201320.","journal-title":"J Intern Med"},{"key":"3558_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.42785","volume":"76","author":"A Fukada","year":"2024","unstructured":"Fukada A, Fujisawa T, Hozumi H, Koda K, Akamatsu T, Oyama Y, et al. Prognostic role of Interferon-\u03bb3 in Anti-Melanoma Differentiation-Associated gene 5-Positive Dermatomyositis-Associated interstitial lung disease. Arthritis Rheumatol. 2024;76:796\u2013805.","journal-title":"Arthritis Rheumatol"},{"key":"3558_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"3558_CR23","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/rheumatology\/keh723","volume":"44","author":"EH Kang","year":"2005","unstructured":"Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3109\/s10165-012-0756-0","volume":"23","author":"S Arai","year":"2013","unstructured":"Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis\/ dermatomyositis. Mod Rheumatol. 2013;23:872\u201383.","journal-title":"Mod Rheumatol"},{"key":"3558_CR25","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57:2114\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2214\/ajr.169.4.9308447","volume":"169","author":"EA Kazerooni","year":"1997","unstructured":"Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977\u201383.","journal-title":"AJR Am J Roentgenol"},{"key":"3558_CR27","doi-asserted-by":"publisher","first-page":"e22978","DOI":"10.1002\/jcla.22978","volume":"33","author":"Y Ye","year":"2019","unstructured":"Ye Y, Fu Q, Wang R, Guo Q, Bao C. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal. 2019;33:e22978.","journal-title":"J Clin Lab Anal"},{"key":"3558_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-019-1835-9","volume":"21","author":"JS Lee","year":"2019","unstructured":"Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther. 2019;21:58.","journal-title":"Arthritis Res Ther"},{"key":"3558_CR29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/rheumatology\/kes012","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012;51:1336\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR30","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1183\/09031936.96.09081736","volume":"9","author":"M Drent","year":"1996","unstructured":"Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9:1736\u201342.","journal-title":"Eur Respir J"},{"key":"3558_CR31","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5\u2009+\u2009dermatomyositis with therapeutic implications. Nat Commun. 2022;13:6458.","journal-title":"Nat Commun"},{"key":"3558_CR32","doi-asserted-by":"publisher","first-page":"103374","DOI":"10.1016\/j.jaut.2025.103374","volume":"151","author":"K Kurasawa","year":"2025","unstructured":"Kurasawa K, Arai S, Taniguchi-Namiki Y, Komatsu S, Shimizu A, Hasegawa A, et al. Pulmonary and serum cytokine profiles of patients with anti-ARS and anti-MDA5 antibodies. J Autoimmun. 2025;151:103374.","journal-title":"J Autoimmun"},{"key":"3558_CR33","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","volume":"60","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhou S, Wu C, Li M, Wang Q, Zhao Y, et al. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis. Rheumatology (Oxford). 2021;60:e227\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR34","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95:e70\u20138.","journal-title":"Neurology"},{"key":"3558_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","volume":"40","author":"Q Yang","year":"2022","unstructured":"Yang Q, Lyu K, Li J, Zhang P, Guan W, Zhang L, et al. Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses. Clin Exp Rheumatol. 2022;40:304\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"3558_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.thromres.2004.02.010","volume":"113","author":"SK Nadar","year":"2004","unstructured":"Nadar SK, Al Yemeni E, Blann AD, Lip GY. Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage\/dysfunction and activation in pregnancy induced hypertension. Thromb Res. 2004;113:123\u20138.","journal-title":"Thromb Res"},{"key":"3558_CR37","doi-asserted-by":"publisher","first-page":"104224","DOI":"10.1016\/j.mvr.2021.104224","volume":"138","author":"MJ Andrianto, Al-Farabi","year":"2021","unstructured":"Andrianto, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Microvasc Res. 2021;138:104224.","journal-title":"Microvasc Res"},{"key":"3558_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"3558_CR39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64:1602\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3558_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.55563\/clinexprheumatol\/ubov8b","volume":"39","author":"C He","year":"2021","unstructured":"He C, Chen J, Luo X, Yan B. Evaluation of biomarkers related to endothelial dysfunction: proof of vasculopathy in anti-melanoma differentiation-associated gene 5 dermatomyositis. Clin Exp Rheumatol. 2021;39:151\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"3558_CR41","first-page":"903","volume":"33","author":"M Funauchi","year":"2006","unstructured":"Funauchi M, Shimadsu H, Tamaki C, Yamagata T, Nozaki Y, Sugiyama M, et al. Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis. J Rheumatol. 2006;33:903\u20136.","journal-title":"J Rheumatol"},{"key":"3558_CR42","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51:1278\u2013784.","journal-title":"Rheumatology (Oxford)"},{"key":"3558_CR43","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51:1563\u201370.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03558-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03558-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03558-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:02:47Z","timestamp":1744812167000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03558-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3558"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03558-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies 2011 of the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan. This study was approved by the Bioethics Committee of Dokkyo Medical University (#22081). Written informed consent was obtained from each patient for the use of serum samples, and clinical and laboratory data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"KK received research support from Asahi-Kasei, Boehringer-Ingelheim, Chugai, Eisai, the Japan Blood Products Organization, and Ono outside the submitted work. KI received research grant from Mitsubishi-Tanabe and Japan Blood Products Organization and speakers fees from Eli Lilly, Abbvie, Eisai, Gilead, Pfizer, AstraZeneca, Asahi-kasei, Novartis, Janssen, Taiho, UCB, Bristol-Myers Squibb, Ono, Chugai, Daiichi Sankyo, GSK, and Mitsubishi-Tanabe outside the submitted work. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}